Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

The deal involves an enterprise value of $85 million plus approximately $75 million in net cash held by FibroGen in China at the time of closing, totaling around $160 million. This strategic move will ...

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...

An expert discusses the case of a patient with metastatic castration-resistant prostate cancer (CRPC) who progressed after ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...